CAPTRUST Financial Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,000	Closed	-$15K	–	5187
2022 Q1	$15K	Hold	2,000	–	–	﹤0.01%	3592
2021 Q4	$20K	Buy	2,000 +1,000	+100%	+$12.7K	﹤0.01%	3294
2021 Q3	$13K	Sell	1,000 -2,000	-67%	-$32.6K	﹤0.01%	3464
2021 Q2	$66K	Hold	3,000	–	–	﹤0.01%	2330
2021 Q1	$72K	Buy	3,000 +2,000	+200%	+$46.5K	﹤0.01%	2181
2020 Q4	$18K	Sell	1,000 -4,000	-80%	-$59.8K	﹤0.01%	2307
2020 Q3	$58K	Hold	5,000	–	–	﹤0.01%	1584
2020 Q2	$119K	Buy	+5,000	New	+$82.7K	﹤0.01%	1267

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAPTRUST Financial Advisors's GTHX Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2022, closing a stake of 2,000 shares — an estimated $15K sold.

CAPTRUST Financial Advisors first reported a position in GTHX in Q2 2020 and held it in 8 quarters. The position peaked at $119K in Q2 2020. 98 funds tracked by Wall St. Rank hold GTHX as of Q2 2022.

CAPTRUST Financial Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 2,000 G1 Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $15K.
CAPTRUST Financial Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
CAPTRUST Financial Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $119K in Q2 2020.
98 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.